BrightSpring Health Raises FY2025 Sales Guidance from $11.60B-$12.10B To $12.00B-$12.50B Vs $11.96B Est; Sees Adjusted EBITDA Of $570M-$585M

Full Year 2025 Financial Guidance

For the full year 2025, BrightSpring is increasing guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2024 Revenue and Adjusted EBTIDA results, excluding the Community Living business.

• Net Revenue of $12,000 million to $12,500 million, or 19.1% to 24.1% growth.
  • Pharmacy Segment Revenue of $10,550 million to $11,000 million, or 20.5% to 25.7% growth.
  • Provider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth.
• Adjusted EBITDA2 of $570 million to $585 million, or 23.9% to 27.2% growth.